SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back


National Association for Continuing Education
Faculty
Mark Brantly, MD
Vice Chair of Research, Department of Medicine
Professor of Medicine, Molecular
Genetics and Microbiology
Alpha One Foundation Research Professor
University of Florida College of Medicine
Gainesville, FL

Course Director and Moderator
Fernando J. Martinez, MD, MS
Executive Vice Chairman
Joan and Sanford I. Weill Department of Medicine
Weill Cornell Medical College
New York, NY

Medical Writer
Josh Kilbridge
Kilbride Associates Healthcare Communications
San Francisco, CA

Title
: Diagnosis and Treatment of the Alpha-1 Antitrypsin Deficiency: A Genetic Subgroup of COPD
Activity/Course #:
: NCME349
Cost:
: Free
Release/Start Date:
: Apr 01 2018
Expiration Date:
: Mar 31 2019
Topics:
: Pulmonology
Target Audience:
: Pulmonologists and Primary Care Providers
Format:
: Webcast
Estimated Time To Complete CME Activity:
: 1.0 Hour
Credit(s):
: 1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s)
Hardware/Software Requirements:
Program Summary
Alpha-1 antitrypsin deficiency (AATD) is characterized by low serum levels of alpha-1 antitrypsin (AAT), a serine protease inhibitor responsible for inhibiting the proteolytic enzyme elastase. The clinical effects of AATD are most frequently found in the lungs, where AATD is associated with an increased risk of developing chronic obstructive pulmonary disease (COPD). Severe AATD poses a significant threat to health, with airflow obstruction being a major determinant of mortality. Over 250,000 individuals in the United States are estimated to have AATD, but the disease often remains unrecognized or undertreated, suggesting that clinicians can benefit from education on this topic. This educational program will highlight the benefits of augmentation therapy in AATD, present data from clinical trials on augmentation therapy and discuss strategies to enhance detection and treatment of AATD in clinical practice.
 
This webcast was recorded live at the Conversations in Pulmonology 2018 Live Virtual Symposium and is being used with the permission of the presenters.

Learning Objectives
After completing this program participants should be able to:
  1. Discuss the relationship between alpha-antitrypsin (AAT) protein variants, serum AAT levels, and chronic obstructive pulmonary disease (COPD) risk.
  2. Review recommendations for screening in AATD.
  3. Review clinical trial data on the use of augmentation therapy for AATD.
  4. Discuss strategies to enhance detection and treatment of AATD in clinical practice.

How to obtain the CME Certificate

  1. Register for the course at www.naceonline.com
  2. View the content.
  3. Complete and submit the post-test and evaluation.
  4. A minimum passing score of 70% must be earned on the post-test in order to complete the CME activity.
  5. Print your CME certificate.
Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.

Fernando Martinez, MD, MS serves as Advisory Board/Steering Committee member to Astra Zeneca, Boehringer Ingelheim, Novartis, Peal, DSMB to Genentech, and Advisor to ProTerrix Bio.

Mark Brantly, MD serves as a consultant for Grifols, serves as the co-owner/director for GeneAidyx and is on the research funding team for the Alpha 1 Foundation.

Gregg Sherman, MD, Activity Planning Committee, has no relationships to disclose.

Josh Kilbridge, Medical Writer, has no relationships to disclose.

Harvey C. Parker, Ph.D., Activity Planning Committee, has no relationships to disclose.

Michelle Frisch, MPH, Activity Planning Committee, has no relationships to disclose.

Sheila Lucas, CWEP, Activity Planning Committee has no relationships to disclose.

Sandy Bihlmeyer, MEd, Activity Planning Committee has no relationship to disclose.

Alan Goodstat, LCSW, Activity Planning Committee, has no relationships to disclose.
Commercial Support
This educational activity is supported by an educational grant from Grifols.